Madrigal Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Madrigal Pharmaceuticals
MDGL Stock  USD 582.34  1.39  0.24%   
Madrigal Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Madrigal Pharmaceuticals' valuation are provided below:
Gross Profit
705.5 M
Profit Margin
(0.39)
Market Capitalization
13.3 B
Enterprise Value Revenue
16.8692
Revenue
740.6 M
There are over one hundred nineteen available fundamental ratios for Madrigal Pharmaceuticals, which can be analyzed over time and compared to other ratios. We recommend to check Madrigal Pharmaceuticals' last-minute fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 130.5 M. The Enterprise Value is projected to slide to about 114.7 M

Madrigal Pharmaceuticals Total Revenue

189.14 Million

Check Madrigal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Madrigal Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 15.4 M, Other Operating Expenses of 711.9 M or Research Development of 248.6 M, as well as many indicators such as Price To Sales Ratio of 39.81, Dividend Yield of 0.0073 or PTB Ratio of 9.14. Madrigal financial statements analysis is a perfect complement when working with Madrigal Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Madrigal Stock
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

Madrigal Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1 B329.6 M
Slightly volatile
Total Stockholder Equity792.1 M754.4 M247.2 M
Slightly volatile
Common Stock Total Equity4.3 K2.3 K4.2 K
Slightly volatile
Common Stock Shares Outstanding22.3 M21.3 M10.5 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1 B329.6 M
Slightly volatile
Other Stockholder Equity2.7 B2.6 B848.9 M
Slightly volatile
Total Liabilities302.3 M287.9 M82.4 M
Slightly volatile
Common Stock3 K1.8 K4.1 K
Slightly volatile
Other Current Liabilities130.9 M124.7 M39.7 M
Slightly volatile
Total Current Liabilities177.7 M169.3 M56.7 M
Slightly volatile
Property Plant And Equipment Net4.8 M4.6 M1.8 M
Slightly volatile
Accounts Payable45.8 M43.6 M11.8 M
Slightly volatile
Cash76.8 M100 M79.3 M
Slightly volatile
Non Current Assets Total9.8 M9.3 M2.6 M
Slightly volatile
Non Currrent Assets Other719.9 K1.4 M775.7 K
Slightly volatile
Cash And Short Term Investments972.6 M926.3 M317.1 M
Slightly volatile
Short Term Investments867.5 M826.2 M237.3 M
Slightly volatile
Other Current Assets19.7 M18.8 M3.6 M
Slightly volatile
Property Plant And Equipment Gross4.8 M4.6 M1.8 M
Slightly volatile
Total Current Assets1.1 B1 B327.6 M
Slightly volatile
Short and Long Term Debt Total125.5 M119.6 M30.6 M
Slightly volatile
Short Term Debt933.9 K983 K5.4 M
Slightly volatile
Long Term Debt Total59.5 M56.7 M43 M
Slightly volatile
Capital Surpluse1.4 B1.3 B742.1 M
Slightly volatile
Capital Lease Obligations2.1 M2 M797.6 K
Slightly volatile
Short and Long Term Debt49.9 M55.9 M47.1 M
Slightly volatile
Net Invested Capital915.5 M872 M333.9 M
Slightly volatile
Net Working Capital906.8 M863.6 M332.2 M
Slightly volatile
Capital Stock1.6 K1.8 K2 K
Slightly volatile
Non Current Liabilities Other445.9 K445.1 K383.1 K
Slightly volatile

Madrigal Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses711.9 M678 M191.2 M
Slightly volatile
Research Development248.6 M236.7 M113.5 M
Slightly volatile
Total Operating Expenses705.4 M671.8 M186.2 M
Slightly volatile
Depreciation And Amortization1 M1.1 M3.4 M
Slightly volatile
Selling General Administrative456.8 M435.1 M77.4 M
Slightly volatile
Interest Income49 M46.7 M10.2 M
Slightly volatile
Non Operating Income Net Other4.1 M2.5 M2.2 M
Slightly volatile
Reconciled Depreciation1.2 M1.1 M308.8 K
Slightly volatile
Selling And Marketing Expenses86.4 M97.2 M106 M
Slightly volatile

Madrigal Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow70.4 M99.9 M70.7 M
Slightly volatile
Depreciation946.6 K696 K553.5 K
Slightly volatile
Other Non Cash Items2 M2.1 M6.3 M
Very volatile
Capital Expenditures732.3 K1.5 M480.7 K
Pretty Stable
Total Cash From Financing Activities771.8 M735.1 M219.5 M
Slightly volatile
End Period Cash Flow76 M105 M78.2 M
Slightly volatile
Stock Based Compensation83.9 M79.9 M23.1 M
Slightly volatile
Change Receivables6.3 K6.6 K20.8 K
Slightly volatile
Change To Netincome38.2 M36.4 M16.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio39.8141.9143.7747
Slightly volatile
Dividend Yield0.00730.00830.009
Slightly volatile
PTB Ratio9.148.70147.9096
Pretty Stable
Days Sales Outstanding119125243
Slightly volatile
Book Value Per Share49.8735.46241.074
Pretty Stable
Average Payables472.1 K497 K884.4 K
Slightly volatile
Stock Based Compensation To Revenue0.480.510.8778
Slightly volatile
Capex To Depreciation1.412.10062.1782
Very volatile
PB Ratio9.148.70147.9096
Pretty Stable
EV To Sales39.9342.0342.0321
Slightly volatile
Inventory Turnover0.180.190.2114
Slightly volatile
Days Of Inventory On Hand1.4 K1.5 K1.7 K
Slightly volatile
Payables Turnover0.310.16810.1939
Slightly volatile
Sales General And Administrative To Revenue1.661.752.707
Slightly volatile
Research And Ddevelopement To Revenue1.441.512.6781
Slightly volatile
Capex To Revenue0.00890.00930.0498
Slightly volatile
Cash Per Share81.543.541263.4785
Pretty Stable
Days Payables Outstanding2.1 K2.2 K228.8 K
Pretty Stable
Income Quality0.570.97780.806
Slightly volatile
Intangibles To Total Assets0.00360.00410.0045
Slightly volatile
Current Ratio7.076.10210.5684
Very volatile
Tangible Book Value Per Share49.8635.239741.0594
Pretty Stable
Receivables Turnover2.863.013.0964
Slightly volatile
Shareholders Equity Per Share49.8735.46241.074
Pretty Stable
Debt To Equity0.170.15850.1858
Slightly volatile
Capex Per Share0.06530.06870.1934
Slightly volatile
Revenue Per Share7.247.627.7617
Slightly volatile
Interest Debt Per Share7.516.31046.389
Slightly volatile
Debt To Assets0.0880.11470.0946
Pretty Stable
Graham Number174196213
Slightly volatile
Operating Cycle1.5 K2.1 K1.8 K
Slightly volatile
Price Book Value Ratio9.148.70147.9096
Pretty Stable
Days Of Payables Outstanding2.1 K2.2 K228.8 K
Pretty Stable
Ebt Per Ebit1.530.93582.3403
Pretty Stable
Effective Tax Rate0.260.30.328
Slightly volatile
Company Equity Multiplier1.451.38161.4494
Pretty Stable
Total Debt To Capitalization0.230.13680.1297
Pretty Stable
Debt Equity Ratio0.170.15850.1858
Slightly volatile
Quick Ratio7.065.900710.5552
Very volatile
Net Income Per E B T0.540.90.6627
Slightly volatile
Cash Ratio0.560.59097.0371
Very volatile
Days Of Inventory Outstanding1.4 K1.5 K1.7 K
Slightly volatile
Days Of Sales Outstanding119125243
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.00321.0126
Pretty Stable
Price To Book Ratio9.148.70147.9096
Pretty Stable
Fixed Asset Turnover37.0835.3134.3135
Slightly volatile
Debt Ratio0.0880.11470.0946
Pretty Stable
Price Sales Ratio39.8141.9143.7747
Slightly volatile
Asset Turnover0.150.160.1612
Slightly volatile
Price Fair Value9.148.70147.9096
Pretty Stable

Madrigal Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap130.5 M198.3 M201.2 M
Pretty Stable
Enterprise Value114.7 M186.2 M188.6 M
Pretty Stable

Madrigal Fundamental Market Drivers

Forward Price Earnings666.6667
Cash And Short Term Investments926.3 M

Madrigal Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Madrigal Pharmaceuticals Financial Statements

Madrigal Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how Madrigal Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-38.7 K-36.8 K
Total Revenue180.1 M189.1 M
Cost Of Revenue6.2 M6.5 M
Stock Based Compensation To Revenue 0.51  0.48 
Sales General And Administrative To Revenue 1.75  1.66 
Research And Ddevelopement To Revenue 1.51  1.44 
Capex To Revenue 0.01  0.01 
Revenue Per Share 7.62  7.24 
Ebit Per Revenue(2.49)(2.61)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:
How To Invest In Madrigal
Details
Is Madrigal Stock a good investment?
Details
What is Madrigal Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Madrigal Pharmaceuticals Correlation against competitors.
For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.
You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.90)
Revenue Per Share
33.392
Quarterly Revenue Growth
3.62
Return On Assets
(0.16)
Return On Equity
(0.41)
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY